| Autor: |
Cieszykowska, Izabela, Rybak, Paweł, Janiak, Tomasz, Żółtowska, Małgorzata, Ochman, Paweł, Steczek, Łukasz, Szczodry, Artur, Lenda-Tracz, Wioletta, Mikołajczak, Renata, Garnuszek, Piotr |
| Zdroj: |
Nuclear Medicine Review; 2024, Vol. 27, p62-71, 10p |
| Abstrakt: |
Background: Therapeutic radiopharmaceuticals [177Lu]Lu-DOTA-TATE and [90Y]Y-DOTA-TATE are used in peptide receptor radionuclide therapy (PRRT) of neuroendocrine tumors. One of the factors determining the efficacy of such therapy is administering the radiopharmaceutical dose to the patients in a way consistent with treatment planning. This paper evaluates the loss of [177Lu]Lu-DOTA-TATE and [90Y]Y-DOTA-TATE and their mixed doses during the administration to the patient either by direct infusion or by gravity method. Material and methods: The loss of [177Lu]Lu-DOTA-TATE and [90Y]Y-DOTA-TATE, was assessed in tests simulating the administration procedures and during infusion to the patients performed at four clinical centres. One clinical centre used a direct infusion, and three others used a gravity method to administer radiopharmaceuticals to the patient. Results: In the direct infusion the highest radioactivity loss was 3.88% ± 0.49% (n = 3) and 3.76% ± 0.83% (n = 3) for [177Lu] Lu-DOTA-TATE infusion with radioactivity of 3.71 GBq ± 0.08 GBq (n = 3) and 1.06 GBq ± 0.08 GBq (n = 3), respectively, and 4.04% ± 0.40% (n = 5) for infusion of [90Y]Y-DOTA-TATE dose of 1.98 GBq ± 0.05 GBq (n = 5). In the gravity method administration of [177Lu]Lu-DOTA-TATE generated losses of up to 1.31% ± 0.46% (n = 16) for a dose of 7.45 GBq ± 0.06 GBq (n = 16) and 2.93% ± 1.64% (n = 8) for a dose of 3.78 GBq ± 0.05 GBq (n = 8). However, the infusion of the lowest doses of 0.95 GBq ± 0.01 GBq (n = 4) [177Lu]Lu-DOTA-TATE and 1.96 GBq ± 0.03 GBq (n = 8) [90Y]Y-DOTA-TATE resulted in higher loss of radiopharmaceuticals up to 6.00% ± 0.97% (n = 4) and 4.00% ± 1.57% (n = 8), respectively. Conclusions: Both investigated methods of radiopharmaceutical administration are associated with the loss of the radioactivity of radiopharmaceutical. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
